KEY POINTS
- This multinational retrospective study from the PORTAL consortium evaluated 177 patients with PSMA-PET-detected oligorecurrent hormone-sensitive prostate cancer who received at least two separate courses of metastasis-directed radiotherapy (MDRT) across 10 centers in five European countries. Oligorecurrence was defined as five or fewer metastases, and patients received MDRT without concurrent or adjuvant androgen deprivation therapy (ADT). Median follow-up after the second MDRT course was 26.1 months.
- All eligible PSMA-PET-positive metastatic lesions were treated using stereotactic radiotherapy, without elective nodal irradiation. Common schedules included 35 Gy in five fractions, 30 Gy in three fractions, 18 Gy in one fraction, and 24 Gy in one fraction, depending on lesion location and institutional practice. Median PSA before the second treatment course was 1.5 ng/mL, and the median interval between the first and second MDRT courses was 16.1 months.
- Following the second MDRT course, median ADT-free survival was 25.4 months (95% CI 18.9–31.8). Estimated ADT-free survival was 79.4% at one year, 50.2% at two years (95% CI 41.4–58.3%), and 36.0% at three years. During follow-up, 86 patients initiated ADT, most commonly after polymetastatic progression (60.5% of ADT initiations), followed by further oligorecurrence unsuitable for local treatment (22.0%).
- At two years, polymetastatic-free survival was 64.4% (95% CI 55.4–72.0%), while next-line systemic therapy-free survival was 83.5% (95% CI 76.0–88.9%) and overall survival was 94.2% (95% CI 88.2–97.2%). A third MDRT course was delivered to 49 patients (27.7%), a fourth to eight, and a fifth to one patient, illustrating the use of repeated local treatment in selected patients with persistently limited metastatic burden.
- Two factors remained independently associated with ADT-free survival after multivariable adjustment. Each additional month between the first and second MDRT courses was associated with a lower hazard of starting ADT (HR 0.96 per month, 95% CI 0.94–0.99; p=0.003), whereas treating two or more lesions versus one lesion was associated with shorter ADT-free survival (HR 1.88, 95% CI 1.22–2.90; p=0.006). PSA doubling time showed a univariable association but did not remain statistically significant in the final model (p=0.073).
- Exploratory subgroup analyses demonstrated substantial outcome heterogeneity. Patients with an interval >18 months between MDRT courses had median ADT-free survival of 62.8 months versus 17.7 months with shorter intervals (p=0.0001). Similarly, patients receiving treatment for one lesion had median ADT-free survival of 32.9 months versus 16.6 months for those with two or more lesions (p=0.0005). The resulting prognostic model achieved an optimism-corrected C-index of 0.68, indicating moderate discrimination.
- Reported treatment toxicity was limited, with four CTCAE grade ≥2 adverse events across all MDRT courses, including pain, diarrhea, urinary frequency requiring medication, and a compression fracture. However, lesion-level local-control data, detailed treatment volumes and uniform imaging schedules were unavailable. Most importantly, the cohort included only patients who had already remained eligible for repeated MDRT, introducing substantial biological selection, while the absence of a comparator group prevents causal conclusions about ADT deferral.
CLINICAL TAKEAWAY
Repeated PSMA-guided metastasis-directed RT may be a reasonable strategy for carefully selected patients with persistently oligorecurrent hormone-sensitive prostate cancer who wish to defer systemic treatment. Longer intervals between metastatic recurrences and fewer lesions identify patients with more favorable outcomes, but the observed ADT-free survival may reflect indolent disease biology as well as treatment effects, and the proposed prediction model requires external validation.